Use of insertable cardiac monitors for the detection of atrial fibrillation in patients with cryptogenic stroke in the United States is cost-effective

References

• Sanna T, Diener H-C, Passman RS. Cryptogenic stroke and atrial fibrillation. N Engl J Med. 2014;371(13):1261.
   PubMedGoogle Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke. 1991;22(8):983–988.
   PubMed Web of Science ®Google Scholar
• Diener H-C, Eikelboom J, Connolly SJ, et al. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol. 2012;11(3):225–231.
   PubMed Web of Science ®Google Scholar
• Easton JD, Lopes RD, Bahit MC, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012;11(6):503–511.
   PubMed Web of Science ®Google Scholar
• Coleman CI, Peacock WF, Bunz TJ, et al. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and previous stroke or transient ischemic attack. Stroke. 2017;48(8):2142–2149.
   PubMed Web of Science ®Google Scholar
• Li L, Yiin GS, Geraghty OC, et al. Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study. The Lancet Neurology. 2015;14(9):903–913.
   PubMed Web of Science ®Google Scholar
• Hart RG, Diener H-C, Coutts SB, et al. Embolic strokes of undetermined source: the case for a new clinical construct. The Lancet Neurology. 2014;13(4):429–438.
   PubMed Web of Science ®Google Scholar
• Verma N, Ziegler PD, Liu S, et al. Incidence of atrial fibrillation among patients with an embolic stroke of undetermined source: insights from insertable cardiac monitors. Int J Stroke. 2019;14(2):146–153.
   PubMed Web of Science ®Google Scholar
• Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366(2):120–129.
   PubMed Web of Science ®Google Scholar
• Kishore A, Vail A, Majid A, et al. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke. 2014;45(2):520–526.
   PubMed Web of Science ®Google Scholar
• Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160–2236.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962.
   PubMed Web of Science ®Google Scholar
• Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46–e110.
   PubMed Web of Science ®Google Scholar
• Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014;370(26):2467–2477.
   PubMed Web of Science ®Google Scholar
• Albers GW, Bernstein RA, Brachmann J, et al. Heart rhythm monitoring strategies for cryptogenic stroke: 2015 diagnostics and monitoring stroke focus group report. J Am Heart Assoc. 2016;5(3):e002944.
   PubMed Web of Science ®Google Scholar
• Piorkowski C, Busch M, Nölker G, et al. Clinical evaluation of a small implantable cardiac monitor with a long sensing vector. Pacing Clin Electrophysiol. 2019;42(7):1038.
   PubMed Web of Science ®Google Scholar
• Reinsch N, Ruprecht U, Buchholz J, et al. The BioMonitor 2 insertable cardiac monitor: clinical experience with a novel implantable cardiac monitor. J Electrocardiol. 2018;51(5):751–755.
   PubMed Web of Science ®Google Scholar
• Giancaterino S, Lupercio F, Nishimura M, et al. Current and future use of insertable cardiac monitors. JACC Clin Electrophysiol. 2018;4(11):1383–1396.
   PubMedGoogle Scholar
• Ziegler PD, Rogers JD, Ferreira SW, et al. Long-term detection of atrial fibrillation with insertable cardiac monitors in a real-world cryptogenic stroke population. Int J Cardiol. 2017;244:175–179.
   PubMed Web of Science ®Google Scholar
• Angelis G. d, Cimon K, Sinclair A, et al. Monitoring for atrial fibrillation in discharged stroke and transient ischemic attack patients: recommendations. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016. (CADTH Optimal Use Report; No. 5.2c)
   Google Scholar
• Kirchhof P. Integrated care of patients with atrial fibrillation: the 2016 ESC atrial fibrillation guidelines. Heart. 2017;103(10):729–731.
   PubMed Web of Science ®Google Scholar
• Conti S, Reiffel JA, Gersh BJ, et al. Baseline demographics, safety, and patient acceptance of an insertable cardiac monitor for atrial fibrillation screening: the REVEAL-AF Study. J Atr Fibrillation. 2017;9(5):1551.
   PubMedGoogle Scholar
• Ciconte G, Giacopelli D, Pappone C. The role of implantable cardiac monitors in atrial fibrillation management. J Atr Fibrillation. 2017;10(2):1590.
   PubMedGoogle Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Diamantopoulos A, Sawyer LM, Lip GYH, et al. Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke. Int J Stroke. 2016;11(3):302–312.
   PubMed Web of Science ®Google Scholar
• Miller JD, Ye X, Lenhart GM, et al. Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US. Clinicoecon Outcomes Res. 2016;8:215–226.
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Antithrombotic agents for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Ottawa (ON): CADTH; 2013.
   Google Scholar
• Diener H-C, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010;9(12):1157–1163.
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Patel MR, Stevens SR, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012;11(4):315–322.
   PubMed Web of Science ®Google Scholar
• Ziegler PD, Rogers JD, Ferreira SW, et al. Real-world experience with insertable cardiac monitors to find atrial fibrillation in cryptogenic stroke. Cerebrovasc Dis. 2015;40(3-4):175–181.
   PubMed Web of Science ®Google Scholar
• Luengo-Fernandez R, Paul NLM, Gray AM, et al. Population-based study of disability and institutionalization after transient ischemic attack and stroke: 10-year results of the Oxford Vascular Study. Stroke. 2013;44(10):2854–2861.
   PubMed Web of Science ®Google Scholar
• Rost NS, Giugliano RP, Ruff CT, et al. Outcomes with edoxaban versus warfarin in patients with previous cerebrovascular events: findings from ENGAGE AF-TIMI 48 (effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction 48). Stroke. 2016;47(8):2075–2082.
   PubMed Web of Science ®Google Scholar
• Sanna T, Ziegler PD, Crea F. Detection and management of atrial fibrillation after cryptogenic stroke or embolic stroke of undetermined source. Clin Cardiol. 2018;41(3):426–432.
   PubMed Web of Science ®Google Scholar
• Sposato LA, Cipriano LE, Saposnik G, et al. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. The Lancet Neurol. 2015;14(4):377–387.
   PubMed Web of Science ®Google Scholar
• Glotzer TV, Ziegler PD. Silent atrial fibrillation as a stroke risk factor and anticoagulation indication. Can J Cardiol. 2013;29(7):S14–S23.
   PubMed Web of Science ®Google Scholar
• Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. Oxford (UK): Oxford University Press; 2006.
   Google Scholar
• Lauffenburger JC, Farley JF, Gehi AK, et al. Factors driving anticoagulant selection in patients with atrial fibrillation in the United States. Am J Cardiol. 2015;115(8):1095–1101.
   PubMed Web of Science ®Google Scholar
• AETNA. Holter Monitors [Internet]. Hartford (CT): AETNA; 2016 [cited 2016 Dec 15]. Available from: http://www.aetna.com/cpb/medical/data/1_99/0019.html.
   Google Scholar
• Shah A, Shewale A, Hayes CJ, et al. Cost-effectiveness of oral anticoagulants for ischemic stroke prophylaxis among nonvalvular atrial fibrillation patients. Stroke. 2016;47(6):1555–1561.
   PubMed Web of Science ®Google Scholar
• Ariesen MJ, Claus SP, Rinkel GJE, et al. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke. 2003;34(8):2060–2065.
   PubMed Web of Science ®Google Scholar
• Paciaroni M, Agnelli G, Caso V, et al. Causes and risk factors of cerebral ischemic events in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants for stroke prevention. Stroke. 2019;50(8):2168.
   PubMed Web of Science ®Google Scholar
• Moerch-Rasmussen A, Nacu A, Waje-Andreassen U, et al. Recurrent ischemic stroke is associated with the burden of risk factors. Acta Neurol Scand. 2016;133(4):289–294.
   PubMed Web of Science ®Google Scholar
• Mohan KM, Crichton SL, Grieve AP, et al. Frequency and predictors for the risk of stroke recurrence up to 10 years after stroke: the South London Stroke Register. J Neurol Neurosurg Psychiatry. 2009;80(9):1012–1018.
   PubMed Web of Science ®Google Scholar
• Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004;110(16):2287–2292.
   PubMed Web of Science ®Google Scholar
• Ntaios G, Papavasileiou V, Diener H-C, et al. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials. Stroke. 2012;43(12):3298–3304.
   PubMed Web of Science ®Google Scholar
• Edlin R, McCabe C, Hulme C, et al. Cost effectiveness modelling for health technology assessment: a practical course. Cham (Switzerland): ADIS; 2015.
   Google Scholar
• Dorian P, Kongnakorn T, Phatak H, et al. Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. Eur Heart J. 2014;35(28):1897–1906.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Kongnakorn T, Phatak H, et al. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. Clin Ther. 2014;36(2):192.e20–210.e20.
   Web of Science ®Google Scholar
• Arias E. United States Life Tables, 2011. Natl Vital Stat Rep. 2015;64(11):1–63.
   PubMedGoogle Scholar
• Group EEATFTS. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. The Lancet. 1993;342(8882):1255–1262.
   PubMed Web of Science ®Google Scholar
• Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health. 2010;13(5):509–518.
   PubMed Web of Science ®Google Scholar
• Miller PSJ, Andersson FL, Kalra L. Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated? Stroke. 2005;36(2):360–366.
   PubMed Web of Science ®Google Scholar
• Cipriano LE, Sposato LA. Estimating the sensitivity of holter to detect atrial fibrillation after stroke or transient ischemic attack without a gold standard is challenging. Am J Cardiol. 2016;117(2):314–316.
   PubMed Web of Science ®Google Scholar
• Choe WC, Passman RS, Brachmann J, et al. A comparison of atrial fibrillation monitoring strategies after cryptogenic stroke (from the cryptogenic stroke and underlying AF trial). Am J Cardiol. 2015;116(6):889–893.
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Waalen J, Edwards AM, et al. Effect of a home-based wearable continuous ecg monitoring patch on detection of undiagnosed atrial fibrillation: the mSToPS randomized clinical trial. JAMA. 2018;320(2):146–155.
   PubMed Web of Science ®Google Scholar
• Reinke F, Bettin M, Ross LS, et al. Refinement of detecting atrial fibrillation in stroke patients: results from the TRACK-AF study. Eur J Neurol. 2018;25(4):631–636.
   PubMed Web of Science ®Google Scholar
• Mairesse GH, Moran P, van Gelder IC, et al. Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLAECE). Europace. 2017;19(10):1589–1623.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–817.
   PubMed Web of Science ®Google Scholar
• Hart RG, Sharma M, Mundl H, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med. 2018;378(23):2191–2201.
   PubMed Web of Science ®Google Scholar
• Diener H-C, Easton JD, Granger CB, et al. Design of randomized, double-blind, evaluation in secondary stroke prevention comparing the efficacy and safety of the oral thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with embolic stroke of undetermined source (RE-SPECT ESUS). Int J Stroke. 2015;10(8):1309–1312.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Keshishian A, Li X, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke. 2018;49(12):2933–2944.
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Förster K, Ebertz F, et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace. 2015;17(4):530–538.
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Ehlken B, Evers T. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace. 2016;18(8):1150–1157.
   PubMed Web of Science ®Google Scholar
• Gallagher AM, Rietbrock S, Plumb J, et al. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?. J Thromb Haemost. 2008;6(9):1500–1506.
   PubMed Web of Science ®Google Scholar
• Nölker G, Mayer J, Boldt L-H, et al. Performance of an implantable cardiac monitor to detect atrial fibrillation: results of the DETECT AF study. J Cardiovasc Electrophysiol. 2016;27(12):1403–1410.
   PubMed Web of Science ®Google Scholar